Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Nephroid Carcinoma: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Nephroid Carcinoma: 1 US clinical trial tracked, none currently recruiting.

Nephroid Carcinoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition nephroid-carcinoma

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Nephroid Carcinoma (this)0%
Open-enrollment share among volume-matched conditions near Nephroid Carcinoma

Nephroid Carcinoma has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Nephroid Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Nephroid Carcinoma is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Nephroid Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

interferon alfa-2a Drug
1 trials
RAD001(everolimus) Drug
1 trials
bevacizumab Drug
1 trials

US sites by state

Facility locations filed on Nephroid Carcinoma trials. A trial with sites in several states counts in each.

Washington 1 trials
Texas 1 trials
Pennsylvania 1 trials
Nevada 1 trials
Michigan 1 trials
California 1 trials
Arkansas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Nephroid Carcinoma page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Nephroid Carcinoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Novartis Pharmaceuticals sponsors the most Nephroid Carcinoma trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Nephroid Carcinoma condition card totals 1 registered trials; most-linked intervention interferon alfa-2a; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.